Search

By assuming primitive regenerative identities, cancer cells gain the adaptability they need to establish tumors in new parts of the body.

Research led by investigators at Memorial Sloan Kettering has identified a previously unknown mechanism of resistance to the newly approved melanoma drug, vemurafenib.

Immunologist Alexander Rudensky and medical oncologist and immunologist Jedd Wolchok are investigating innovative ways to use the immune system to fight cancer.